EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?

被引：81

作者：

Ke, E-E ^{[1
,2
]}

Wu, Yi-Long ^{[1
,2
]}

机构：

[1] Guangdong Acad Med Sci, Guangdong Lung Canc Inst, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China

[2] Guangdong Acad Med Sci, Guangdong Gen Hosp, 106 Zhongshan 2nd Rd, Guangzhou 510080, Guangdong, Peoples R China

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2016年 / 37卷 / 11期

关键词：

GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; CIRCULATING TUMOR DNA; PHASE-II TRIAL; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; BRAIN METASTASES; C797S MUTATION; ASIAN PATIENTS;

D O I：

10.1016/j.tips.2016.09.003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors (TKIs) is highly effective in terms of tumor response rate, survival, and quality of life. However, acquired resistance to EGFR-TKIs is inevitable. Ongoing clinical trials will provide evidence for optimal strategies for patients with EGFR mutant non-small-cell lung cancer (NSCLC) in the near future. Numerous new agents are specifically addressing resistance mechanisms; mature data are related to the T790M mutation and MET pathway activation. Here, we provide a comprehensive review of new perspectives on how to optimize the management of this molecular disease.

引用

页码：887 / 903

页数：17

共 119 条

[1] Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial [J].

Ahn, M. -J. ;

Yang, J. ;

Yu, H. ;

Saka, H. ;

Ramalingam, S. ;

Goto, K. ;

Kim, S. -W. ;

Yang, L. ;

Walding, A. ;

Oxnard, G. R. .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) :S115-S115

[2] AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies [J].

Ahn, M. J. ;

Tsai, C. M. ;

Yang, J. C. H. ;

Shepherd, F. A. ;

Satouchi, M. ;

Kim, D. W. ;

Bazhenova, L. ;

Hirashima, T. ;

Rukazenkov, Y. ;

Cantarini, M. ;

Mann, H. ;

Ramalingam, S. S. ;

Mitsudomi, T. ;

Jaenne, P. A. ;

Goss, G. D. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S625-S626

[3] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[4]

[Anonymous], J CLIN ONCOL

[5]

[Anonymous], LUNG CANC

[6]

[Anonymous], J CLIN ONCOL

[7]

[Anonymous], BR J CANC

[8]

[Anonymous], J CLIN ONCOL

[9]

[Anonymous], J CLIN ONCOL

[10]

[Anonymous], J CLIN ONCOL

← 1 2 3 4 5 6 7 8 9 10 →